Dalzell A M, Bartlett H, Lilleyman J S
Arch Dis Child. 1986 May;61(5):502-5. doi: 10.1136/adc.61.5.502.
A prospective randomised double blind crossover trial was conducted comparing the new synthetic cannabinoid nabilone with oral domperidone in a group of children receiving repeated identical courses of emetogenic chemotherapy for a variety of malignant diseases. Eighteen of 23 consecutive eligible children, aged 10 months to 17 years, completed the trial. When taking nabilone they experienced significantly fewer vomiting episodes and less nausea, and two thirds expressed a preference for the drug. The most common side effects of treatment with nabilone were somnolence and dizziness, with one patient being disturbed by hallucinations. The results indicate that nabilone is an effective antiemetic for children having chemotherapy, even for young children. It seems to be superior in this respect to domperidone, and although it has a higher incidence of side effects, these are mostly acceptable to patients. It can be recommended as an alternative to conventional antiemetic treatment throughout childhood.
开展了一项前瞻性随机双盲交叉试验，在一组因各种恶性疾病接受重复相同疗程致吐性化疗的儿童中，将新型合成大麻素纳布啡与口服多潘立酮进行比较。23名年龄在10个月至17岁之间的连续合格儿童中有18名完成了试验。服用纳布啡时，他们经历的呕吐发作明显减少，恶心程度也减轻，并且三分之二的儿童表示更喜欢这种药物。纳布啡治疗最常见的副作用是嗜睡和头晕，有一名患者受到幻觉困扰。结果表明，纳布啡对接受化疗的儿童，甚至对幼儿来说，是一种有效的止吐药。在这方面它似乎优于多潘立酮，尽管其副作用发生率较高，但大多为患者所接受。它可被推荐作为整个儿童期常规止吐治疗的替代药物。
